Idarubicin

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Adverse-effects 4 Test-interactions 5 More General Terms 6 Additional Terms 7 Internet Database 8 References

Introduction

• Tradename: Idamycin.

Indications

• used in combination treatment of acute myeloid leukemia, including FAB classification M1-M7
• non-Hodgkin's lymphoma

• Powder for injection: ( lyophilized) 5 mg, 10 mg.

Adverse-effects

• common (> 10%)

• infection, nausea/vomiting, alopecia, diarrhea, hemorrhage, mucositis, reddish urine, fever, headache, leukopenia, thrombocytopenia

• less common (1-10%)

• seizure, wheezing, peripheral neuropathy

• uncommon (< 1%)

• myocardial toxicity, congestive heart failure, acute life-threatening arrhythmias
  
• drug adverse effects of anthracyclines

Test-interactions

• increased serum urea nitrogen, creatinine, AST, ALT, K+, uric acid

More General Terms

• anthracycline
• antineoplastic agent (chemotherapeutic agent)

Additional Terms

• daunorubicin, daunomycin; DNR (Cerubidine, DaunoXome)

Internet Database

PubChem: 42890
PubChem: 42593
PubChem: 636362
PubChem: 3685
PubChem: 444091

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
2. Department of Veterans Affairs, VA National Formulary

idarubicin; 4-methoxydaunorubicin (Idamycin)